Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3946 - High Response Rate with T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Melanoma

Presenters

Viola Franke

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

V. Franke1, D.M.S. Berger2, W.M.C. Klop2, B. van der Hiel3, B.A. van de Wiel4, S. Ter Meulen1, M. Wouters1, W. van Houdt5, A.C.J. van Akkooi5

Author affiliations

  • 1 Surgical oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 2 Head And Neck Surgery And Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 3 Nuclear Medicine, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 4 Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 5 Surgical oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3946

Background

Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1 (HSV-1), which can be administered intralesionally in patients with stage IIIB/C-IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%.

Methods

Since approval of T-VEC in the Netherlands in December 2016, 35 eligible patients started treatment with T-VEC monotherapy at the Netherlands Cancer Institute. We included 23 patients with a follow up time ≥6 months. Analysis of overall response rate (ORR), adverse events (AE), prior treatment for melanoma and baseline characteristics, documented in a prospectively maintained database. Besides clinical evaluation, in this study we used PET-CT and histological biopsies for response evaluation.

Results

The median follow-up was 11.3 months. Of 23 patients, 12 (52.2%) had a complete response (CR) as their best response, all except for one ongoing after stopping treatment. As their best response, 7 (30.4%) patients had a partial response (PR), 2 (8.7%) patients had a mixed response and 2 (8.7%) patients showed progressive disease (PD). ORR for the analyzed cohort was 82.6%. Disease Control Rate (DCR) was 91.3%. At baseline, the mean number of lesions was between 5 and 50 lesions. Grade 1-2 AE’s occurred in all patients. Mostly, these consisted of fatigue, influenza-like symptoms and injection site pain. 1 patient had to pause treatment due to ≥grade 3 AE (colitis). Prior treatment was documented: all 23 patients underwent surgical resection, 13 isolated limb perfusion (56.5%), 1 targeted therapy (4.3%), 2 immunotherapy (8.7%), 2 radiotherapy (8.7%). Prior treatment did not influence response or toxicity of T-VEC. PET-CT and biopsies proved to be a clinically useful tool to evaluate treatment response for T-VEC monotherapy, confirming pCR or PD to stage IV disease requiring systemic treatment.

Conclusions

ORR for T-VEC monotherapy at our institute was 82.6% with 52.2% achieving a CR. This prospective study for T-VEC in early metastatic (stage IIIB/C-IVM1a) melanoma demonstrated superior results to the phase 3 OPTiM study and confirms the role of oncolytic immunotherapy for melanoma.

Clinical trial identification

Legal entity responsible for the study

Alexander C.J. van Akkooi.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

V. Franke: Travel grant, Research funding: Amgen. A.C.J. van Akkooi: Honoraria: Amgen, Novartis, MSD/Merck; Travel cost: Amgen, Novartis, MSD/Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.